What are our pharmacotherapeutic options for MERS-CoV?
- 3 March 2014
- journal article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 7 (3) , 235-238
- https://doi.org/10.1586/17512433.2014.890515
Abstract
Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease.Keywords
This publication has 26 references indexed in Scilit:
- Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapyInternational Journal of Infectious Diseases, 2013
- Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential TherapeuticsPLoS Pathogens, 2013
- MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatmentJournal of General Virology, 2013
- Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2013
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic PotentialmBio, 2013
- The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus InhibitorsPLoS Pathogens, 2011
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Severe acute respiratory syndrome: report of treatment and outcome after a major outbreakThorax, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004